Welcome to Labtec

Labtec GmbH, an innovative and internationally oriented pharmaceutical company, is focussed on

research and development of drug delivery systems

• transdermal delivery systems
• buccal/gingival delivery systems
• fast dissolving oral dosage forms and
  
  

contract analytics according to international standards.

 

 

 

Labtec NEWS

 

Aug 08: Ondansetron RapidFilm™ licensed to BioAlliance Pharma for Europe

 

Feb 08: APR Applied Pharma Research and Labtec announce the successful completion of the Pilot Bioequivalence study of their Donepezil RapidFilm™

 

Jan 08: APR Applied Pharma Research and Labtec announce the successful completion of the Pivotal Bioequivalence study for their proprietary Ondansetron RapidFilm™

 

 Nov 07: Inauguration of Labtec´s new company building by the mayor of Langenfeld

Apr 07: Labtec’s next generation pain patch successful in clinical studies

Mar 07: Labtec and APR announce positive results for Ondansetron RapidFilm

Jan 07: First continuous combined hormone replacement patch approved for marketing in Europe

Jan 07: Labtec hires new Director of Pharmaceutical Development

Sep 06: Fentanyl patch developed by Labtec GmbH first generic to be approved for marketing in Canada

Jul 06: RapidFilm: Oral Thin Films (OTF) as an Innovative Drug Delivery System and Dosage Form

Mar 06: Labtec and APR sign partnership agreement
for Oral Thin Films

Jan 06: Fentanyl patch developed by Labtec GmbH approved for marketing in Germany

Jan 06: LabiPatch®: Labtec´s revolutionary novel approach to treatment of Herpes labialis